Jie Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jie Sun has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Dongrui Wang
Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication - Fangyang Hu
State Key Laboratory of Lithospheric and Environmental Coevolution, Institute of Geology and Geophysics Chinese Academy of Sciences Beijing 100029 PR China
1 shared publication - Feng Cong
Chengdu Center of China Geological Survey, Chengdu, China
1 shared publication - Fu-Yuan Wu
State Key Laboratory of Lithospheric and Environmental Coevolution, Institute of Geology and Geophysics, Chinese Academy of Sciences, Beijing, China
1 shared publication - Guang-Hui Wu
Wuhan University
1 shared publication Guang-Ming Chen
Refrigeration and Cryogenic Engineering Institute, Zhejiang University, Hangzhou 310027, China
1 shared publication
Latest Publications
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF20
Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is characterized by significant immunosuppression, limiting the efficacy of immunotherapy. Monocytic AML presents unique immunosuppressive features and constitutes a challenging subtype, necessitating focused investigation. Using single-cell multiomic analyses of primary AML samples, we revealed the immunosuppression landscape of monocytic AML and identified biliverdin reductase B (BLVRB) as a marker of immunosuppressive monocytic AML cells. BLVRB depletion downregulated immunomodulatory gene expression and sensitized AML cells to T-cell cytotoxicity, resulting in improved therapeutic efficacy in cell line–derived xenograft (CDX) and patient-derived xenograft (PDX) models. Mechanistically, BLVRB signals through the transcription factor MAFB to promote the expression of various immunosuppression-associated genes, resulting in inhibitory effects against anti-AML T cells. We further demonstrated that the small-molecule tamibarotene targets BLVRB, enhancing the efficacy of both chimeric antigen receptor (CAR) T and anti–PD-1 antibody therapies in AML. These findings elucidate the critical mechanism regulating immunosuppression in monocytic AML and identify BLVRB as a therapeutic target for improving AML immunotherapy. Significance: We revealed the particularly immunosuppressive feature of the monocytic AML subset and identified BLVRB-targeting strategies to reverse AML immunosuppression. Genetic disruption or pharmacologic inhibition of BLVRB sensitized AML cells to T cell–mediated cytotoxicity, offering potential strategies to enhance the therapeutic potency of immunotherapy against AML.
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF20
Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is characterized by significant immunosuppression, limiting the efficacy of immunotherapy. Monocytic AML presents unique immunosuppressive features and constitutes a challenging subtype, necessitating focused investigation. Using single-cell multiomic analyses of primary AML samples, we revealed the immunosuppression landscape of monocytic AML and identified biliverdin reductase B (BLVRB) as a marker of immunosuppressive monocytic AML cells. BLVRB depletion downregulated immunomodulatory gene expression and sensitized AML cells to T-cell cytotoxicity, resulting in improved therapeutic efficacy in cell line–derived xenograft (CDX) and patient-derived xenograft (PDX) models. Mechanistically, BLVRB signals through the transcription factor MAFB to promote the expression of various immunosuppression-associated genes, resulting in inhibitory effects against anti-AML T cells. We further demonstrated that the small-molecule tamibarotene targets BLVRB, enhancing the efficacy of both chimeric antigen receptor (CAR) T and anti–PD-1 antibody therapies in AML. These findings elucidate the critical mechanism regulating immunosuppression in monocytic AML and identify BLVRB as a therapeutic target for improving AML immunotherapy. Significance: We revealed the particularly immunosuppressive feature of the monocytic AML subset and identified BLVRB-targeting strategies to reverse AML immunosuppression. Genetic disruption or pharmacologic inhibition of BLVRB sensitized AML cells to T cell–mediated cytotoxicity, offering potential strategies to enhance the therapeutic potency of immunotherapy against AML.
- 31 August 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (5) , 1944-1952
The role of CBFβ::MYH11 fusion gene in acute lysis pneumopathy: A dual impact on risk and prognosis
Summary: Acute lysis pneumopathy (ALP) is a rare but fatal complication that can occur during induction chemotherapy for newly diagnosed acute myeloid leukaemia (AML). Currently, there is a paucity of large case reports detailing high‐risk and poor prognostic factors associated with its occurrence. To provide evidence‐based guidance on ALP, we conducted a retrospective analysis of 608 patients with newly diagnosed AML (non‐M3), among whom 20 developed ALP during hydroxycarbamide (hydroxyurea) therapy and/or induction chemotherapy, resulting in an overall incidence rate of 3.3% (20/608) and a mortality rate of 35% (7/20). Multivariable logistic regression revealed that male (odds ratio [OR] 5.852, 95% confidence interval [CI]: 1.006–34.028, p = 0.049), elevated leucocyte counts (OR 1.125, 95% CI: 1.050–1.205, p = 0.001) and CBFβ::MYH11 fusion positivity (OR 13.821, 95% CI: 3.002–63.634, p = 0.001) were independent risk factors for the occurrence of ALP. Notably, CBFβ::MYH11 fusion positivity was associated with improved survival in ALP patients ( p = 0.015). This study provides preliminary insights into the risk and prognostic factors of ALP.
- 31 August 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (5) , 1944-1952
The role of CBFβ::MYH11 fusion gene in acute lysis pneumopathy: A dual impact on risk and prognosis
Summary: Acute lysis pneumopathy (ALP) is a rare but fatal complication that can occur during induction chemotherapy for newly diagnosed acute myeloid leukaemia (AML). Currently, there is a paucity of large case reports detailing high‐risk and poor prognostic factors associated with its occurrence. To provide evidence‐based guidance on ALP, we conducted a retrospective analysis of 608 patients with newly diagnosed AML (non‐M3), among whom 20 developed ALP during hydroxycarbamide (hydroxyurea) therapy and/or induction chemotherapy, resulting in an overall incidence rate of 3.3% (20/608) and a mortality rate of 35% (7/20). Multivariable logistic regression revealed that male (odds ratio [OR] 5.852, 95% confidence interval [CI]: 1.006–34.028, p = 0.049), elevated leucocyte counts (OR 1.125, 95% CI: 1.050–1.205, p = 0.001) and CBFβ::MYH11 fusion positivity (OR 13.821, 95% CI: 3.002–63.634, p = 0.001) were independent risk factors for the occurrence of ALP. Notably, CBFβ::MYH11 fusion positivity was associated with improved survival in ALP patients ( p = 0.015). This study provides preliminary insights into the risk and prognostic factors of ALP.
- 24 June 2025
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 26 (7) , 1-5
A case of cardiac arrest and spontaneous renal hemorrhage in a male patient with persistent eosinophilia: highlighting the importance of early diagnosis of eosinophilic granulomatosis with polyangiitis
摘要 嗜酸性肉芽肿性多血管炎(EGPA)是一种罕见的多系统性疾病, 其诊断充满挑战, 尤其是在病情复杂且发病率低的情况下。本文报告了一例58岁男性患者, 既往有10年哮喘病史和1年特发性嗜酸性粒细胞增多症(I-HES)病史。患者因持续性嗜酸性粒细胞增多并伴随心脏骤停和自发性肾出血(SRH)而住院治疗。经心肺复苏后, 患者因肾破裂出血接受了右肾切除术, 肾脏活检结果显示血管闭塞及嗜酸性粒细胞浸润, 最终确诊为EGPA。患者在糖皮质激素和免疫抑制剂联合治疗后取得显著疗效。本文强调了早期识别和及时干预在EGPA管理中的重要性。
- 24 June 2025
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 26 (7) , 1-5
A case of cardiac arrest and spontaneous renal hemorrhage in a male patient with persistent eosinophilia: highlighting the importance of early diagnosis of eosinophilic granulomatosis with polyangiitis
摘要 嗜酸性肉芽肿性多血管炎(EGPA)是一种罕见的多系统性疾病, 其诊断充满挑战, 尤其是在病情复杂且发病率低的情况下。本文报告了一例58岁男性患者, 既往有10年哮喘病史和1年特发性嗜酸性粒细胞增多症(I-HES)病史。患者因持续性嗜酸性粒细胞增多并伴随心脏骤停和自发性肾出血(SRH)而住院治疗。经心肺复苏后, 患者因肾破裂出血接受了右肾切除术, 肾脏活检结果显示血管闭塞及嗜酸性粒细胞浸润, 最终确诊为EGPA。患者在糖皮质激素和免疫抑制剂联合治疗后取得显著疗效。本文强调了早期识别和及时干预在EGPA管理中的重要性。
- 4 November 2010
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 11 (11) , 889-894
Preliminary study on the freeze-drying of human bone marrow-derived mesenchymal stem cells
Long-term preservation and easy transportation of human bone marrow-derived mesenchymal stem cells (hBM-MSCs) will facilitate their application in medical treatment and bioengineering. A pilot study...
- 4 November 2010
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 11 (11) , 889-894
Preliminary study on the freeze-drying of human bone marrow-derived mesenchymal stem cells
Long-term preservation and easy transportation of human bone marrow-derived mesenchymal stem cells (hBM-MSCs) will facilitate their application in medical treatment and bioengineering. A pilot study...